1-7 of 7
Haichao Zhang
Close
Sort by
Journal Articles

The Combinatorial Activity of Eftozanermin (ABBV-621), a Novel and Potent TRAIL Receptor Agonist Fusion Protein, in Pre-Clinical Models of Hematologic Malignancies

Morey L Smith, MS, Sha Jin, MS, Dong Chen, MS, Haichao Zhang, PhD, Jason Huska, PhD, Deborah Widomski, Vicky Bontcheva, Greg Buchanan, PhD, Susan Morgan-Lappe, PhD, Darren C. Phillips, PhD, Stephen K Tahir, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41.
https://doi.org/10.1182/blood-2020-136155
Published: 2020
Journal Articles

Abbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors

Stephen Kenneth Tahir, PhD, Morey L Smith, MS, Larry R Solomon, PhD, Haichao Zhang, PhD, John C Xue, MD, Yu Xiao, MS, Dong Cheng, MS, Greg Buchanan, PhD, Susan Morgan-Lappe, PhD, Darren C. Phillips, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2812.
https://doi.org/10.1182/blood.V130.Suppl_1.2812.2812
Published: 2017
Journal Articles

CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1

Jun Chen, MDPhD, Sha Jin, MS, Paul Tapang, Stephen K Tahir, PhD, Morey Smith, John Xue, Haichao Zhang, PhD, Wenqing Gao, PhD, Yunsong Tong, PhD, Richard Clark, Justin L. Ricker, MD PhD, Thomas D Penning, PhD, Daniel H Albert, PhD, Darren C Phillips, PhD, Andrew J Souers, PhD, Joel D. Leverson, PhD
Journal: Blood
Blood (2014) 124 (21): 2161.
https://doi.org/10.1182/blood.V124.21.2161.2161
Published: 2014
Journal Articles

The Bcl-2 Family Protein Inhibitor, ABT-263, Promotes Apoptotic-Like Response in Isolated Platelets.

Chris Tse, PhD, Haichao Zhang, PhD, Jun Chen, PhD, Ryan M. Fryer, PhD, Richard Nelson, Paul Nimmer, Glenn A. Reinhart, PhD, Morey L. Smith, Stephen K. Tahir, PhD, Saul H. Rosenberg, PhD, Steven W. Elmore, PhD
Journal: Blood
Blood (2006) 108 (11): 1122.
https://doi.org/10.1182/blood.V108.11.1122.1122
Published: 2006
Journal Articles

The Bcl-2 Family Inhibitor ABT-263 Shows Significant but Reversible Thrombocytopenia in Mice.

Alex R. Shoemaker, PhD, Michael J. Mitten, B.S., Jessica Adickes, B.S., Anatol Oleksijew, B.S., Haichao Zhang, Ph.D., Joy Bauch, B.S., Kennan Marsh, Ph.D., David J. Frost, Ph.D., David Madar, Ph.D., Christin Tse, Ph.D., Stephen W. Fesik, Ph.D., Saul H. Rosenberg, Ph.D., Steven W. Elmore, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 1107.
https://doi.org/10.1182/blood.V108.11.1107.1107
Published: 2006
Journal Articles

The Bcl-2 Family Inhibitor ABT-263 Shows Significant Anti-Tumor Efficacy in Models of B Cell Non-Hodgkin’s Lymphoma.

Alex R. Shoemaker, PhD, Michael J. Mitten, B.S., Anatol Oleksijew, B.S., Jacqeuline M. O’Connor, Baole Wang, M.D., Scott Ackler, Ph.D., Mary Joseph, Ph.D., Haichao Zhang, Ph.D., Paul Nimmer, B.S., Yu Xiao, B.S., Christin Tse, Ph.D., David J. Frost, Ph.D., Stephen W. Fesik, Ph.D., Saul H. Rosenberg, Ph.D., Steven W. Elmore, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 825.
https://doi.org/10.1182/blood.V108.11.825.825
Published: 2006
Journal Articles

Survivin does not inhibit caspase-3 activity

Damon P. Banks, Janet Plescia, Dario C. Altieri, Jun Chen, Saul H. Rosenberg, Haichao Zhang, Shi-Chung Ng
Journal: Blood
Blood (2000) 96 (12): 4002–4003.
https://doi.org/10.1182/blood.V96.12.4002
Published: 2000